New crown vaccine | AstraZeneca CEO interviewed that its vaccine can prevent the British variant virus

Instant International

Written by: Cao Jiajun

2020-12-28 03:27

Last update date: 2020-12-28 03:28

Pascal Soriot, chief executive of AstraZeneca, a British pharmaceutical company, said in an interview that researchers believe that the new coronavirus pneumonia (COVID-19) vaccine developed by AstraZeneca and Oxford University is effective Prevent the mutant virus that ravages Britain.

When Soriot was interviewed by The Sunday Times, when asked whether the vaccine could prevent the British variant virus, he said: "So far, we believe that the vaccine (AstraZeneca) is still effective, but we are not sure, so it will be carried out. Related tests."

The Hong Kong government pre-purchases three new coronavirus pneumonia vaccines, including Kexing Holdings inactivated vaccine, Fosun Pharma/German pharmaceutical company BioNTech nucleic acid vaccine, and AstraZeneca/Oxford University virus vector vaccine.

(Profile picture)

Preliminary data indicates that the effective rate of the AstraZeneca vaccine is about 70%, while the effective rate of the vaccine jointly developed by Pfizer and BioNTech is 95%. In contrast, the efficacy seems to be relatively inferior.

Soriot responded that AstraZeneca's researchers have found a winning formula that makes the vaccine as effective as its opponents, but cannot disclose more for the time being and will make an announcement when appropriate.

↓If you want to know the lives of people in other countries during the epidemic, please click to enlarge and watch:

AstraZeneca announced earlier that it would spend 39 billion U.S. dollars (about 304.2 billion yuan) to acquire American biotechnology company Alexion at a price premium of 45% over the biotechnology company’s closing price in the United States last Friday.

AstraZeneca pointed out that the transaction will help strengthen the company's immunology capabilities and can be combined with cancer, cardiovascular and other diseases.

AstraZeneca's chief executive Soriot said that researchers believe that the vaccine developed by AstraZeneca and Oxford University can effectively prevent the mutant virus that ravages the UK.

(Gettyimages)

New Coronary Pneumonia Vaccine | 7 pictures to see the side effects of the protection rate of Kexing, BioNTECH Fosun, AstraZeneca

New coronary pneumonia | AstraZeneca developed antibody drug may achieve immediate immune effect

New Coronary Pneumonia Vaccine Q&A｜Can you choose?

Efficient?

Coxing, Fosun, AstraZeneca side effects

01News

New crown pneumonia UK outbreak (new crown pneumonia) UK variant virus vaccine new crown vaccine